News

OXLUMO® (lumasiran injection) Now Reimbursed in Canada For the Treatment of Primary Hyperoxaluria Type 1 (PH1) in Pediatric and Adult Patients
Alnylam Canada ULC is pleased to announce that OXLUMO® (lumasiran) is now funded across Canada through both public and ...
The Pharma Letter1d
Vutrisiran nod sets stage for shake-up in rare disease space
Alnylam Pharmaceuticals (Nasdaq: ALNY) has won European Commission approval for Amvuttra (vutrisiran) to treat transthyretin ...
Alnylam Pharma Stock Outlook: Is ALNY Topping Out?
Alnylam Pharmaceuticals ALNY +1.01% Get Free Report is currently in Phase 10 of its 18-phase Adhishthana Cycle. With this phase scheduled to end in September 2025, the stock remains within its bullish ...
Possible Bearish Signals With Alnylam Pharmaceuticals Insiders Disposing Stock
The fact that multiple Alnylam Pharmaceuticals, Inc. ( NASDAQ:ALNY ) insiders offloaded a considerable amount of ...
Managed Healthcare Executive2d
Rare Diseases: Once Lightning Strikes, Now Lightning Storms
For payers, claims for rare disease treatments used to be uncommon. Not anymore, thanks to an increasing number of new, ...
$1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today
Buying $1000 In ALNY: If an investor had bought $1000 of ALNY stock 5 years ago, it would be worth $2,172.18 today based on a price of $322.83 for ALNY at the time of writing.
BMO Capital Maintains ‘Outperform’ Rating on Alnylam Pharmaceuticals, Inc. (ALNY); Raises PT
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is among the best stocks added in a Growth Stock Portfolio.
Medscape6d
Sclerosing Mesenteritis: What GIs Need to Know About This Rare Disease
With CT scans picking up more cases of sclerosing mesenteritis, be prepared to diagnose this poorly understood autoimmune ...
Alnylam Pharma (ALNY) Gets a Buy from BMO Capital
Detailed price information for Alnylam Pharmaceuticals (ALNY-Q) from The Globe and Mail including charting and trades.